TABLE 1.
Patient and disease characteristics
| Characteristic | Regorafenib, n (%) | Regorafenib and PD‐1 antibody, n (%) | p |
|---|---|---|---|
| Age | 0.012 | ||
| >60 | 29 (30.5) | 12 (14.3) | |
| ≤60 | 66 (69.5) | 72 (85.7) | |
| Sex | 0.448 | ||
| Female | 36 (37.9) | 37 (44.0) | |
| Male | 59 (62.1) | 47 (56.0) | |
| Primary tumor location | 0.931 | ||
| Right‐sided | 30 (31.6) | 25 (29.8) | |
| Left‐sided | 37 (38.9) | 35 (41.7) | |
| Rectum | 28 (29.5) | 24 (28.6) | |
| Metastasis site | |||
| Liver | 0.417 | ||
| Involved | 69 (72.6) | 56 (66.7) | |
| Noninvolved | 26 (27.4) | 28 (33.3) | |
| Lung | 0.544 | ||
| Involved | 58 (61.1) | 47 (56.0) | |
| Noninvolved | 37 (38.9) | 37 (44.0) | |
| Distant lymph node | 0.049 | ||
| Involved | 33 (34.7) | 42 (50.0) | |
| Noninvolved | 62 (65.3) | 42 (50.0) | |
| Peritoneal | 0.646 | ||
| Involved | 34 (35.8) | 33 (39.3) | |
| Noninvolved | 61 (64.2) | 51 (60.7) | |
| RAS | 0.372 | ||
| Wild‐type | 41 (43.2) | 42 (50.0) | |
| Mutated | 54 (56.8) | 42 (50.0) | |
| BRAF | 0.050 | ||
| Wild‐type | 92 (96.8) | 74 (88.1) | |
| V600E mutated | 1 (1.1) | 7 (8.3) | |
| Non‐ V600E mutated | 2 (2.1) | 3 (3.6) |